Safety Study of Nivolumab for Selected Advanced Malignancies in India

Trial Profile

Safety Study of Nivolumab for Selected Advanced Malignancies in India

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 12 Mar 2018 Planned End Date changed from 21 Apr 2020 to 29 Apr 2020.
    • 12 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 26 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top